cyrilzakka/clinical-trials huggingface dataset:
The Effects of Different Anesthetics on Functional Connectivity

This research is a prospective cohort study. The aim of the study is to determine different levels of sedative mechanism and the effect on brain functional connectivity of midazolam, dexmedetomidine and propofol.

This research will include 120 healthy volunteers and 120 brain tumor patients; the participants will be allocated into midazolam, dexmedetomidine and propofol group. Resting and task fMRI will be performed at awake (BIS\>90), mild sedation (BIS 80-85), moderate sedation (BIS 65-75), deep sedation (BIS 45-55) and recovery states (BIS \>90). The primary outcome of our study is the effect of different levels of sedation for brain network connection. The secondary outcomes are the effect of different levels of sedation for default, executive control, sensory and motor networks and their subnetwork connectivity; the sedation state, circulatory and respiratory parameters of the participants, and the adverse events.

Eligibility Criteria:
Inclusion Criteria:

* 1. Male, 18 \~ 65 years old
* 2. Healthy Volunteer / Brain Tumor Patients
* 3. Senior high school and above
* 4. Sign informed consent

Exclusion Criteria:

* 1. In vivo implant MRI check taboo
* 2. Cardiopulmonary liver and kidney and other systemic complications
* 3. History of major surgical anesthesia
* 4. Abuse of drugs, alcoholism history
* 5. Test drug allergy history
* 6. Claustrophobia
* 7. Left hand
Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository

The Morphea in Adults and Children (MAC) cohort is the first registry for both children and adults with morphea (also known as localized scleroderma) in the country. The purpose of the registry is to learn more about morphea, specifically:

* How morphea behaves over time
* How frequently specific problems occur along with morphea (for example, arthritis)
* Whether morphea has an autoimmune background


Eligibility Criteria:
Inclusion Criteria:

1. Patient must have a clinical diagnosis of morphea confirmed by the primary investigator and by histopathological examination.
2. Ages 0-90 years old
3. Children must weigh more than 20 lbs. in order to satisfy Children's Medical Center policy for the maximum amount of blood drawn in a 24 hour period.
4. Patient or legal guardian must be able to speak and read at a 6th grade reading level.
5. Both male and female patients will be eligible
6. All races and ethnic backgrounds will be included
7. Relationships to proband: All patients with morphea will be included. A patient's family history will be reviewed and if there is a family history of morphea or systemic sclerosis then we will give the study patient the investigator's contact information and ask the family member to call the study team to answer any questions and enroll them in the study if they choose to do so.
8. Ability to give informed consent: Patients must be able to give informed consent or they will give assent with parent or guardian consent as a minor to be a part of the morphea registry.

Exclusion Criteria:

- Patients who have been coded as morphea (701.0), but do not have morphea/localized scleroderma (examples: steroid atrophy, acquired keratoderma, keloids, nephrogenic fibrosing dermopathy, systemic sclerosis, lichen sclerosis)
Endoscopic-assisted Microsurgical Removal of Cerebellopontine Angle Lesions

It is a Prospective descriptive hospital based clinical study to determine the value of introduction of endoscope after microscopic excision of cerebello-pontine angle lesions to estimate the following :

1. Intraoperative judgement of lesions excision, residual parts, visualization and operative corridor pre and after endoscope introduction.
2. Post-operative tumor control confirmed comparison between pre and postoperative MRI.
3. Postoperative complications, advantages and disadvantages compared with these when use pure microscopic excision from the literature


Eligibility Criteria:
Inclusion Criteria: cerebellopontine angle lesions

* meningeoma.
* vestibular schwannoma.
* arachnoid cyst.
* petroclival meningeoma.

Exclusion Criteria:

* trigeminal neuralgia.
* facial neuralgia.
Advance® 18PTX® Balloon Catheter Study

The Advance® 18 PTX® Balloon Catheter study is a clinical trial to study the safety and effectiveness of the Advance 18® PTX® Balloon Catheter in the treatment of lesions in the superficial femoral artery and popliteal artery.


Eligibility Criteria:
Key Inclusion Criteria:

* Age \>18 years.
* Able to provide informed consent.
* Has at least one de novo or restenotic lesion(s) with \> 70% stenosis documented angiographically of the SFA or popliteal artery. If more than one lesion requires intervention, only one should be treated as a study lesion.

Key Exclusion Criteria:

* Has significant stenosis (\> 50%) or occlusion of inflow tract (proximal ipsilateral, iliofemoral, or aortic lesions) not successfully treated before this procedure.
* Lack of at least one patent runoff vessel with \< 50% stenosis throughout its course.
* Lesions in target area requiring atherectomy (or ablative devices), cutting balloons, cryoplasty balloons, or any other advanced device to facilitate angioplasty balloon or stent delivery.
The Utility of Circulating Tumour Cells and Plasma microRNA in Esophageal Adenocarcinoma

Circulating microRNA (circ miRNA) and circulating tumor cell (CTC) levels are hypothesized to be associated with response to chemoradiation in patients undergoing treatment for locally advanced esophageal adenocarcinoma.

The goal of this project is to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.

Recently, different groups have discovered that miRNAs can be detected in body fluids such as plasma, serum or saliva. These cell-free miRNAs are secreted by cells under different forms. Levels of these circulating miRNAs (circ miRNA), like tissue miRNA, were closely related to pathologies and could be used as diagnostic or prognostic tools for several pathologies, including cancer. Furthermore, a recent report showed that circ miRNAs released by tumor cells have the ability to transfer their metastatic potential to nonmetastatic cells. The detection and analysis of circulating miRNA represent a new step towards non-invasive diagnostic screening and early cancer detection.

Circulating tumor cells also hold promise as biological markers, which can be assessed noninvasively. As more than 90% of cancer deaths are associated with metastasis, it is crucial to understand the mechanisms of dissemination of cancer cells. During the past decade, a multitude of techniques have been developed to track down and to characterize CTC. Clinical studies in various cancers reveal the potential of CTC as prognostic and predictive markers. The characterization of CTC will help to design personalized treatment to eradicate the sub-clones of the primary tumour, which give rise to metastasis. Also, the numbers of CTC in patient blood can be followed to monitor the efficacy of the neoadjuvant treatment.

Most of the research in esophageal cancer has been done on squamous cell cancer as this is the dominant cell type worldwide. However, beginning the in 1980s Esophageal Adenocarcinoma (EAC) has increased in frequency such that it now represents 80% of esophageal cancer in North America and Europe. There is an urgent need to develop new techniques and diagnostic tests to combat EAC. By combining circ miRNA and CTC, we not only combine 2 promising clinical biomarkers, we will also be able to access new data that will complement tissue biopsy data. Furthermore, by acquiring a blood sample during various time points of patient treatment, we will be able to create a dynamic CTC and circ miRNA profile.

Eligibility Criteria:
Inclusion Criteria:

* Patients who are at least 18 years of age
* Patients with Esophageal Adenocarcinoma who will undergo neo-adjuvant therapy with surgical resection.
* Patients with esophageal adenocarcinoma who will be treated with chemotherapy, chemotherapy and radiation or radiation alone OR
* Healthy volunteers who are at least 18 years of age

Exclusion Criteria:

* Patients who are treated with surgery alone for esophageal cancer
* Patients who have a history of invasive cancer
Eight Week Strength Training Reduces Blood Pressure of Middle Age Women

Introduction: Strength training (ST) is an important non-pharmacological means to reduce blood pressure (BP). Objective: To verify the pressure response of women after 8 weeks of ST. Method: Fourteen women were divided into young group (YG) and middle age (MAG) and submitted to ST for 8 weeks, lasting 60 minutes in 11 alternating exercises per segment with intensity of 12 to 13 on the subjective perception scale of effort. BP was verified at weeks 1, 4 and 8.

The sample consisted of 14 women, which were divided into two groups: young group (YG = 7) and middle age group (MAG = 7). Inclusion criteria were: females aged 18 to 59 years, sedentary or who had not been engaged in any physical activity in the last 6 months, and the availability of time three times a week in the afternoon shift. Exclusion criteria were: morbid obesity (BMI\> 40 kg.m-2), presenting any osteo-articular dysfunction.

After the adaptation period, resistance exercise sessions were started, which were performed 3 times a week on alternate days, in which each session lasted 60 minutes, and performed for a period of 8 weeks. Each session consisted of 10-minute warm-up on the treadmill or bicycle, shortly after, starting the exercises in the form of alternating circuit by segment, as: machine bench press, extension chair, high pull (front), flexor table, direct curl, leg press, triceps pulley, adductor, abdominal, abductor and calf. In all 10 exercises, 3 sets of 8 to 12 repetitions were performed, with an interval of 60 seconds between sets and intensity of 12 arbitrary units (a.u.) to 14 a.u., measured by the rate perception effort scale. In the first, fourth and eighth week, pre-exercise blood pressure (BP) was verified, in which the participants sat for a period of 10 minutes at rest, in a comfortable chair, with legs uncrossed, feet flat on the floor, back leaning on the chair, left arm at heart level and palm up1 to measure BP using a G \* Tech-branded automatic digital device (MASTER MA100 model).

Eligibility Criteria:
Inclusion Criteria:

* Females between 18 and 59 years old, sedentary or who had not been engaged in any physical activity in the last 6 months, plus the availability of time three times a week in the afternoon shift.

Exclusion Criteria:

* Morbid obesity (BMI\> 40 kg.m-2), presenting any osteo-articular dysfunction that limited the performance of exercises in strength training, women who were classified in category 3 (known serious disease) after risk stratification of the College American of Sports Medicine and also, who presented cardiovascular diseases, autonomic neuropathy, diabetes and hypertension controlled or not.
Dark Chocolate and Glucose Levels in Diabetes

Diabetes is a growing concern in the world with an estimated 9.3% of adults, ages 20-79, with it in 2019, type 2 diabetes accounting for 90% of this total. A common recommendation for individuals with diabetes is to limit sugars and sweets as it may cause a high blood glucose response. As a result, chocolate is often avoided due to the sugar content; though, high-polyphenol chocolate may have a beneficial effect on hyperglycaemia and vascular function. The sugar-free chocolate from Ross Chocolates is formulated with a blend of inulin, erythritol, and stevia. These alternatives to sugar are not expected to cause a significant change in blood glucose levels following consumption. The main objective of this study is to verify glucose levels before and after consumption of Ross Chocolates' blend of sweeteners dark chocolate and conventional chocolate in people with diabetes.

Individuals with type 1 or type 2 diabetes (10 participants each) will consume a Ross Chocolate or conventional sugar-sweetened dark chocolate bar on two occasions in a randomized crossover trial. Blood glucose levels will be measured by finger prick for 120 minutes after consumption to determine postprandial glucose excursions after consumption of each type of chocolate bar.

Due to the COVID-19 pandemic, the trial was converted to be completed remotely/virtually with participants completing the testing at their home under the supervision of a research team member who will describe the study procedures and monitor testing via video conferencing.

Eligibility Criteria:
Inclusion Criteria:

* physician-diagnosed T1D or T2D of ≥1 year;
* current HbA1c of 6.5-8.5%;
* BMI: 25-40 kg/m2;
* blood pressure of \<160/99 mm Hg assessed according to guidelines;
* non-smoking;
* not on hormone replacement therapy, corticosteroids, or anti-inflammatory medications;
* 18-75 years old.

Exclusion Criteria:

* Are taking more than 2 glucose lowering medications;
* Are ongoing medical treatment for diseases such as cancer, auto-immune or inflammatory disease, liver or kidney disorders;
* Have allergy, intolerance or aversion to cocoa, stevia, erythritol, inulin, or any other dietary restrictions (e.g., vegan) that will prevent them from following the standardized study diets;
* Are unable to follow remote guidance by internet or smartphone;
* Are unable to follow the controlled diet instructions;
* Are unable to read or communicate in English.
Qualitative and Quantitative Evaluation of Anosmia Over Time in Clinically Symptomatic Patients Tested for COVID-19 Infection

Loss of sense of smell and taste has been anecdotally reported during the covid-19 epidemic. The study investigators wanted to describe the prevalence of olfactory and gustatory dysfunction and assess the factors associated with positive SARS-CoV-2 infection.


Eligibility Criteria:
Inclusion Criteria:

* Patients presenting with COVID-19 related symptoms including: fever, persistent cough, fatigue, shortness of breath, diarrhoea, abdominal pain, chest pain, sore throat, loss of smell or taste
* Subjects in prolonged contact with COVID-19 infected patients.

Exclusion Criteria:

* Patients directly admitted to the intensive care unit were excluded
* Patients opposing use of their health data
Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer

This is observational clinical trial to study adult urothelial cancer patients treated with cisplatin-based neoadjuvant chemotherapy.

Hypothesis: Identification of genetic and molecular "cisplatin susceptibility" biomarkers will allow identification of urothelial cancer patients most likely to benefit from cisplatin-based neoadjuvant chemotherapy.

In this trial patients will submit germline (blood) and tumor tissue samples as part of two existing sample collection protocols for analysis of genetic and molecular markers governing response to chemotherapy. Pathologic review of tissue samples after neoadjuvant therapy will allow determination of the complete response rate (pT0 rate) and this will be compared between patients with "susceptible" and "resistant" genetic/molecular cisplatin susceptibility variants.

Primary Endpoint: Analysis of whether a small set of previously-identified germline "cisplatin susceptibility" polymorphisms associate with achievement of a complete pathologic response to neoadjuvant cisplatin-based chemotherapy in urothelial cancer patients.

Secondary Endpoints: To perform companion genetic or molecular analyses of other previously-identified gene, SNP, or microRNA "cisplatin susceptibility" candidates in these patients, using tumor and/or germline tissue.

Exploratory Endpoints: To perform unbiased, hypothesis-generating SNP, gene, or microRNA array studies to identify novel germline or tumor determinants which may predict response to cisplatin-based chemotherapy.

Eligibility Criteria:
Inclusion Criteria:

* Patients with clinical T2 through T4 urothelial carcinoma of the bladder or upper tract.
* Patients must be deemed appropriate by the treating physician to require cisplatin-based neoadjuvant chemotherapy for urothelial cancer. Consideration of regional nodal status as part of the decision for appropriateness for neoadjuvant chemotherapy will be left to the treating physician.
* Patients must be scheduled to proceed to definitive urothelial cancer surgery, including either cystectomy or nephrectomy/ureterectomy, after chemotherapy.
* Age \>18 years.

Exclusion Criteria:

* Patients receiving cisplatin-based chemotherapy for urothelial cancer in the adjuvant setting or for metastatic disease.
Validity and Reliability of The Turkish Version of Assessment of Burden of COPD Scale

In our study, we aimed to evaluate the validity and reliability of the Turkish version of theAssessment of Burden of COPD (ABC) Scale.

Chronic obstructive pulmonary disease (COPD) is a common pulmonary disease characterized by airway limitation, irreversible, preventable, and treatable (1,2). COPD is a major health problem that affects the entire world and is expected to be the fourth, the seventh, cause of death in 2030 (3). The concept of "holistic assessment of disease burden" is widely used to support the personalized care management of COPD patients. Disease burden; physical, psychological, emotional and / or social burden felt by the patient. When the questionnaires in the literature evaluating the quality of life / health status in COPD patients were examined, it was seen that none of these questionnaires included all aspects of COPD burden definition (4). Clinical COPD Questionnaire (CCQ) is a 10-question questionnaire that assesses COPD burden in most aspects and situations. Assessment of Burden of COPD (ABC) Scale was developed to evaluate the burden of disease in COPD patients by adapting this questionnaire. The ABC scale was formed by combining three items (a short tool for early identification of distress) and a substance that measures fatigue with the questions of the CCQ scale. As a result, a scale of 14 items with 5 fields was formed.

Eligibility Criteria:
Inclusion Criteria:

* FEV1/FVC\<%70
* To be able to read and understand Turkish

Exclusion Criteria:

* Having undergone a COPD exacerbation in the last 6 weeks
* Having comorbidities affecting ambulance
* Having cognitive disorders
Developing and Testing an Implementation Strategy for Active Learning to Promote Physical Activity in Children

The purpose of this study is to develop an implementation strategy to improve the use and sustainment of active learning in elementary schools and to conduct a feasibility study to evaluate the impact of the developed implementation strategy on the implementation and effectiveness of active learning.


Eligibility Criteria:
Inclusion Criteria:

* lead teachers who teach kindergarten to fifth grade
* children in kindergarten to fifth grade

Exclusion Criteria:

* non English or Spanish speaking
Use of Platelet Rich Plasma Therapy for Acute Ankle Sprains in the Emergency Department

This research study hopes to determine whether or not platelet rich plasma therapy improves healing time of moderate to severe ankle sprain in comparison to standard of care therapy.

The intention of this research project is to study a new treatment for severe ankle sprains.This new treatment is called Platelet Rich Plasma (PRP) therapy and involves injecting concentrated platelet's from a patient's own blood into the site of injury to aid healing. Platelets, aside from their clotting capabilities also serve a role in re-vascularization of tissue as well as collagen repair. PRP therapy has been used in sports medicine for treatment of chronic injuries but has yet to be proven effective in acute injury of a joint. The investigators are comparing treatment and placebo groups based on a subjective patient questionnaire and pain score administered on the day of injury and 2-3 days and 8-10 days follow up.

Eligibility Criteria:
Inclusion Criteria:

* severe ankle sprain
* X-ray completed

Exclusion Criteria:

* Pregnancy/breastfeeding
* Police custody
* active infection
* metastatic disease/tumors
* History of thrombocytopenia
* Allergy to ester or amine anesthetics
* On anticoagulant medication
* Peripheral vascular disease
* Known coagulopathy
RosaC-RF : Bipolar Radiofrequency vs Doxycycline in Rosacea

Rosacea is a chronic facial disfiguring dermatosis characterized by different stages like flushing, erythema, telangiectasia and papulo-pustular lesions. Recommended treatments include topical (metronidazole) and systemic (doxycycline) antibiotics with only a suspensive effect. The bipolar radiofrequency (RF) with Elos system (infrared light) is a device emitting an electromagnetic current inducing an increase in temperature when applied on the skin, potentiated by infrared light. The monopolar RF has already been used in rosacea on a small number of cases with positive and prolonged results. RF with Elos system has been evaluated on erythemato-telangiectasic rosacea with encouraging results. Demodex folliculorum (DF) is a long transparent mite which asymptomatically parasitizes pilosebaceous follicle of normal human skin sometimes responsible of inflammatory facial dermatoses. The prevalence and density of DF are increased in rosacea, and DF is suspected to play a role in the pathogenesis of rosacea. DF is sensitive to heat, and the investigators hypothesize that radiofrequency treatment may affect the survival of the mite and should be effective to treat papulopustular rosacea.


Eligibility Criteria:
Inclusion Criteria:

* Subjects must be between 18-70 years old
* Subjects with papulopustular rosacea graded moderate to severe (2 or 3) according to the physician global Assessment, and with lesions on the cheeks.
* Prior stop of any topical treatment antibiotic, retinoid, corticoid or other topical treatment for rosacea at least 1 month before the start of the study
* Prior stop of any systemic treatment (antibiotic) two month before the start of the study and for isotretinoin at least 6 months
* Last laser treatment, by lamp, laser or LED, at least 3 months before the start of the study
* Subjects must be abble to lie for more than 30 minutes
* Patient able to understand and sign the informed consent form
* Affiliation to a social security scheme

Exclusion Criteria:

* Women of child bearing/reproductive potential
* Other skin disease or abnormality of the face which could interfere with the evaluation of the different criteria evaluated or with the realization of the RF
* Contraindications to radiofrequency: presence of a defibrillator or pacemaker, dental on the cheeks, dental equipment or metallic orthopedic next to the treated area, skin cancer on the face, progressive systemic disease, uncontrolled hypertension
* Immunosuppression by HIV (determined by examination) or treatment with immunosuppressive
* Tattoos or permanent makeup on the face
* Excessively tanned skin to sunlight, ultraviolet or with tanning creams during the last 2 weeks
* Subject carrying cochlear implants or open wound or in the process of healing
* Minor patient or under tutorship
* Cyanoacrylate or doxycycline allergy
The Jewels in Our Genes Study - an African American Family Study of Breast Cancer

The research team is studying why some African American families have multiple cases of breast cancer.

This study will help to better understand if there are undiscovered genes unique to African Americans that may predict early breast cancer risk.

Breast cancer survivors AND their relatives who are also breast cancer survivors are being recruited to the study.


Eligibility Criteria:
Inclusion Criteria:

* Black/African American
* Ever diagnosed with breast cancer
* Have at least one living blood relative ever diagnosed with breast cancer, who is also willing to participate
* Live in the U.S.

Exclusion Criteria:

* Tested positive for BRCA mutations